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Islet b-cell dysfunction and aggressive macrophage
activity are early features in the pathogenesis of type 1
diabetes (T1D). 12/15-Lipoxygenase (12/15-LOX) is in-
duced in b-cells and macrophages during T1D and pro-
duces proinﬂammatory lipids and lipid peroxides that
exacerbate b-cell dysfunction and macrophage activity.
Inhibition of 12/15-LOX provides a potential therapeutic ap-
proach to prevent glycemic deterioration in T1D. Two in-
hibitors recently identiﬁed by our groups through screening
efforts, ML127 and ML351, have been shown to selectively
target 12/15-LOX with high potency. Only ML351 exhibited
no apparent toxicity across a range of concentrations in
mouse islets, and molecular modeling has suggested re-
duced promiscuity of ML351 compared with ML127. In
mouse islets, incubation with ML351 improved glucose-
stimulated insulin secretion in the presence of proinﬂam-
matory cytokines and triggered gene expression pathways
responsive to oxidative stress and cell death. Consistent
with a role for 12/15-LOX in promoting oxidative stress, its
chemical inhibition reduced production of reactive oxygen
species in both mouse and human islets in vitro. In a
streptozotocin-induced model of T1D in mice, ML351 pre-
vented the development of diabetes,with coincident enhance-
ment of nuclear Nrf2 in islet cells, reduced b-cell oxidative
stress, and preservation of b-cell mass. In the nonobese
diabetic mouse model of T1D, administration of ML351
during the prediabetic phase prevented dysglycemia, re-
duced b-cell oxidative stress, and increased the propor-
tion of anti-inﬂammatory macrophages in insulitis. The data
provide the ﬁrst evidence to date that small molecules that
target 12/15-LOX can prevent progression of b-cell dys-
function and glycemic deterioration in models of T1D.
Diabetes is a disorder of glucose homeostasis that results
from relative or absolute deﬁciency of insulin. In type 2
diabetes, a state of tissue insulin resistance prevails, and
insulin-producing b-cells are unable to secrete sufﬁcient in-
sulin to overcome this resistance (1). By contrast, type 1 di-
abetes (T1D) is characterized by autoimmune-targeted
destruction of b-cells, resulting in a state of absolute insulin
deﬁciency (2). Whereas orally bioavailable small molecules
have been developed and approved to prevent or treat type 2
diabetes, no such agents have been introduced to prevent or
reverse the b-cell destruction seen in T1D. A challenge in
the development of pharmacotherapies for T1D is the iden-
tiﬁcation of speciﬁc pathways and targets that contribute
to aggressive immune responses and/or b-cell death. Appre-
ciation is increasing for oxidative stress and associated
pathways within the b-cell that may predispose the b-cell to
death upon activation of autoimmunity in T1D (3–5).
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12/15-Lipoxygenase (12/15-LOX) is an enzyme encoded
by the Alox15 gene whose eicosanoid products contribute
to inﬂammatory responses in macrophages and b-cells in
the setting of diabetes (6). In mice, 12/15-LOX catalyzes
the oxygenation of arachidonic acid at the 12 and 15 posi-
tions to form 12- and 15-hydroxyeicosatetraenoic acid
(HETE), respectively, in an;6:1 ratio (7). Global Alox152/2
mice are protected from diabetes in response to low-dose
streptozotocin (STZ) (8), and Alox152/2 mice on the non-
obese diabetic (NOD) background are protected from the
development of T1D in this model (9). Despite a central role
for the adaptive immune system in the inﬂammation asso-
ciated with T1D, studies have suggested that the primary
site of action of 12/15-LOX in conferring T1D risk may be
in inﬁltrating macrophages and the b-cell itself, where it
promotes oxidative and endoplasmic reticulum stress (10).
Accordingly, we have shown that pancreas-speciﬁc Alox15
knockout mice are protected from diabetes in the low-dose
STZ model of T1D, raising the possibility that loss of 12/15-
LOX in b-cells may be sufﬁcient to prevent hyperglycemia
in T1D, despite the continued presence of the enzyme in
macrophages (11).
Apart from its role in T1D pathogenesis, 12/15-LOX and
its lipid products (e.g., 12-HETE) have also been impli-
cated in a variety of other inﬂammatory diseases, including
obesity and insulin resistance (11–13), cardiovascular dis-
ease (14,15), and stroke (16,17), as well as in neurodegen-
erative diseases (18,19). Therefore, the development of
speciﬁc 12/15-LOX inhibitors would have utility across a
range of disorders. The absence of such speciﬁc and potent
inhibitors of the LOX enzymes led members of our group to
perform high-throughput screening to identify novel small-
molecule inhibitors (20–23). Some of these inhibitors spe-
ciﬁcally protected b-cell lines and primary mouse and
human islets from proinﬂammatory cytokine-induced dysfunc-
tion and death (24,25), but to date, none have been tested in
models of diabetes in vivo. ML351 is a small-molecule in-
hibitor of 12/15-LOX with high potency and selectivity ver-
sus other LOX and cyclooxygenase enzymes (16,17). We
sought to determine the efﬁcacy of ML351 in models of
T1D in vitro and in vivo, with a focus on its effects in islets.
RESEARCH DESIGN AND METHODS
Cells, Animals, and Assays
Mouse bTC3 b-cells were cultured and maintained as pre-
viously described (26). Mouse islets were isolated from
collagenase-perfused pancreata as previously described (27), and
human islets were obtained from the Integrated Islet Distribu-
tion Program. Cell cultures were treated with a cytokine cocktail
containing 5 ng/mL interleukin-1b, 10 ng/mL tumor necrosis
factor-a, and 100 ng/mL interferon-g and/or with ML351
for 24 h. Caspase-3 activation assay was performed by using
the Apo-ONE Homogeneous Caspase-3/7 Assay (Promega).
Static glucose-stimulated insulin secretion (GSIS) assays and
immunostaining for reactive oxygen species (ROS) with Cell-
ROX (Invitrogen) were performed as previously described (11).
Male C57BL/6J mice and female NOD/ShiLTJ (NOD)
mice were purchased from The Jackson Laboratory. Female
CD1 mice were purchased from Charles River Laboratories.
Mice were maintained at the Indiana University vivarium
according to protocols approved by the institutional animal
care and use committee. Mice were injected intraperito-
neally (IP) daily with ML351 dissolved in 80:17:3 PBS:
cremophor:ethanol or vehicle alone. Glucose measurements
and IP glucose tolerance tests (GTTs) were performed as
described (28). Mice were euthanized, serum/pancreata har-
vested, and insulin measured as previously described (28).
Pharmacokinetic Analyses
ML351 was synthesized as described previously (23). ML351
was quantiﬁed in plasma and tissue by high-performance
liquid chromatography-tandem mass spectrometry (AB
SCIEX QTRAP 5500) by using temazepam as the internal
standard. Pharmacokinetic parameters for ML351, includ-
ing area under the curve (AUC) and t1/2, were estimated by
using noncompartmental methods. The maximum plasma
concentration (Cmax) and time of Cmax (tmax) were obtained
from the data. The AUC from 0 to inﬁnity (AUC0-∞) was
estimated from the AUC0-t (time zero to the last quantiﬁ-
able concentration [Clast]) and the AUC from Clast to inﬁnity
Clast/kel, where kel is the rate constant of elimination.
Immunohistochemistry and Immunoﬂuorescence
Pancreata were ﬁxed and immunostained as previously
described (29) by using the antibodies indicated in Supple-
mentary Table 1. 4-Hydroxynonenal (4-HNE) and glutathi-
one peroxidase (GPX1) immunostainings were quantiﬁed by
measuring pixel density per insulin-positive cell. Nrf2 was
quantiﬁed by measuring nuclear and cytoplasmic pixel den-
sity per insulin-positive cell. Images were acquired with an
LSM 700 confocal microscope (Zeiss). b-Cell mass and insu-
litis were calculated and scored from immunohistochemical
staining as described previously (28,30) by using at least three
pancreas sections 70 mm apart from ﬁve mice per group.
Docking of LOX Inhibitors to the Human Proteome
Fragment-based ﬂexible docking method CANDOCK (31)
was used to compute compound-proteome interaction sig-
natures of the LOX inhibitors ML127 and ML351 with the
human proteome, as done previously (31–34). Compound-
proteome interaction scores of ML127 and ML351 were
obtained with ;50% of the human proteome (14,595 hu-
man proteins) consisting of previously selected experimen-
tal and computationally modeled protein structures (31,33,34),
where docking was done with only the ﬂexibility of small
molecules and not the proteins with default CANDOCK
parameters. A total of 5,423 human proteins was also an-
notated into druggable protein classes (33) to predict tox-
icity of ML127 and ML351.
RNA Sequencing Analysis
RNA from treated islets (four biologic replicates per
condition) was isolated with RNeasy Mini Kit (QIAGEN)
and used to prepare a dual-indexed nonstranded cDNA
library by using a SMART-Seq v4 Ultra Low Input RNA Kit
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(Clontech). Libraries were sequenced with a HiSeq 4000 sys-
tem (Illumina). All sequenced libraries were mapped to the
mouse genome (University of California, Santa Cruz,
Genome Browser assembly ID mm10) by using STAR
RNA-seq aligner (35). The reads distribution across the ge-
nome was assessed by bamutils (from NGSUtils) (36).
Uniquely mapped sequencing reads were assigned to
mm10 refGene genes through featureCounts (from Sub-
read) (37). Data were normalized by using the trimmed
mean of M values method. Differential expression analysis
was performed by DESeq2 (38). The Benjamini-Hochberg
procedure was used to adjust P values for multiple hypoth-
esis testing. For volcano plots, the fold change (log2 scale)
differences in genes between groups were plotted on
the x-axis, and the P values (–log10 scale) were plotted on
the y-axis by using R (version 3.2) and the ggplot2 package
(version 2.2.1). Gene ontology enrichments (enrichGO, Bi-
ological Processes) were performed by using the R package
clusterProﬁler (version 3.4.4, Bioconductor) (39).
Statistical Analysis
All data are presented as the mean 6 SEM. One-way
ANOVA (with Dunnett posttest) was used for comparisons
involving more than two conditions, and a two-tailed
Student t test was used for comparisons involving two
conditions. Prism 7 software (GraphPad) was used for all
statistical analyses. Statistical signiﬁcance was assumed at
P , 0.05.
RESULTS
Effects of LOX Inhibitors on Cell Viability
Several potent small-molecule inhibitors of human 12-LOX
and 15-LOX enzymes were identiﬁed through quantitative
high-throughput screening (20–22,24). Not previously
tested was compound ML351, a mixed inhibitor that dis-
played nanomolar potency (IC50 ;200 nmol/L) against hu-
man 15-LOX (23). We ﬁrst tested the effect of ML351 on
cell apoptosis in mouse islets (Fig. 1A) and compared its
effects with that of a related 12/15-LOX inhibitor, ML127
(Fig. 1B). As shown in Fig. 1A and B, ML351 displayed no
deleterious effects on cellular apoptosis (by caspase activity
assay) in the range between 1 and 50 mmol/L, whereas
apoptosis was evident with ML127 at a concentration of
50 mmol/L (Fig. 1B). These studies suggest that ML127 ex-
hibits greater cellular toxicity than ML351.
Figure 1—Toxicity of 12/15-LOX inhibitors in mouse islets. A: Chemical structure of ML351 and caspase activity measurements performed with
mouse islets in the presence of varying doses of ML351 for 24 h. B: Chemical structure of ML127 and caspase activity measurements performed
with mouse islets in the presence of varying doses of ML127 for 24 h. C: Distribution of CANDOCK scores with the number of human proteins
predicted to bind to ML127 and ML351. Scores less than a cutoff of 239.13 are predicted strong binders for both compounds. D: Number of
predicted strong binders for ML127 and ML351 distribution in eight druggable protein classes. E: 12-HETE levels in media from mouse islets
incubated with the indicated concentrations of ML351 and proinﬂammatory cytokines for 4 h. Data are mean 6 SEM (n = 3 independent
experiments). *P < 0.05 for the comparisons indicated. GPCR, G-protein–coupled receptor; RFU, relative ﬂuorescence unit.
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Figure 2—12/15-LOX inhibition protects against cytokine-induced islet dysfunction and oxidative stress. A: Mouse islets were incubated for 24 h
with cytokines, ML351, and 12-HETE before exposure to low (2.5 mmol/L) and high (25 mmol/L) glucose, after which insulin levels in the medium
were measured (n = 3–4 independent experiments). *P< 0.05 compared with control conditions (no cytokines, no ML351, no 12-HETE). B: Total
islet insulin content for the insulin release experiments shown in A. C: Volcano plot of RNA sequencing analysis of mouse islets treated with
cytokines + 10 mmol/L ML351 vs. cytokines alone for 24 h (n = 3 independent experiments; red, genes signiﬁcantly altered [P < 0.05]; yellow,
genes altered more than twofold; green, genes signiﬁcantly altered more than twofold). D: Gene ontology pathway analysis of data shown in
C. E: bTC3 b-cells were transfected with Nrf2-Luc reporter and incubated with ML351 at the concentrations indicated and then treated for 6 h
with cytokine before luciferase activity measurement (n = 10 independent experiments). Data are luciferase activity normalized to control
conditions (no cytokines, no ML351). *P < 0.05 compared with untreated control (no cytokines, no ML351). #P < 0.05 compared with cytokine
treatment alone (no ML351). F: Mouse islets stained for ROS (CellROX reagent) (red) and DAPI (blue) upon treatment with or without cytokines
and 10 mmol/L ML351. G: Human islets stained for ROS (CellROX reagent) (red) and DAPI (blue) upon treatment with or without cytokines and
10 mmol/L ML355. Original magniﬁcation 3200; scale bars = 100 mm. Bar graphs show quantitation of CellROX intensity in 10–16 islets from
three independent mouse islet preparations (or human donors). *P< 0.05 compared with untreated islets (no cytokines, no ML compound). Data
are mean 6 SEM. PIC, proinﬂammatory cytokines.
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Because toxicity often is related to off-target effects, we
performed docking in silico of these inhibitors with ;50%
of the human proteome (14,595 proteins). We restricted
the analysis to the human proteome because comprehen-
sive structural data for the mouse proteome are unavailable.
As shown in Fig. 1C, ML127 has a signiﬁcantly lower dis-
tribution of scores than ML351 (Kolmogorov-Smirnov test
with P , 2.2e-16), suggesting that ML127 is a stronger
interactor with non-LOX proteins (lower score = stronger
interaction). By using a binding score of 239.13 (the score
for the binding of ML127 to human 15-LOX, the ortholog
of mouse 12/15-LOX) as a cutoff to predict off-target
interactions, we identiﬁed 4,115 interacting proteins for
ML127 and only 843 interacting proteins for ML351 (Sup-
plementary Table 2 shows a complete list of scores). We
separated the selected binders into druggable classes (chan-
nels, G-protein–coupled receptors, kinases, ligases, nuclear
receptors, proteases, phosphatases, transporters). As shown
in Fig. 1D, ML127 is predicted to bind to a substantially
larger number of proteins than ML351, providing a possible
explanation for its increased toxicity. We next tested the
ability of ML351 to inhibit 12-HETE production in mouse
islets. As shown in Fig. 1E, ML351 decreased 12-HETE
release into islet medium at a dose of 10 mmol/L, but this
effect was unexpectedly not observed at 50 mmol/L.
Effects and Mechanisms of ML351 on Cytokine-Induced
Islet Dysfunction
To determine whether ML351 protects mouse islets in a
T1D model in vitro, we performed coincubation experi-
ments by using ML351 and proinﬂammatory cytokines
(interleukin-1b, tumor necrosis factor-a, interferon-g) (40)
and measured GSIS. Compared with untreated islets, islets
exposed to proinﬂammatory cytokines for 24 h exhibited
increased insulin release at 2.5 mmol/L glucose (evidence of
degranulation) and impaired insulin release in response to
25 mmol/L glucose (Fig. 2A). However, concurrent treat-
ment with 10 mmol/L ML351 restored insulin secretion
at 2.5 mmol/L glucose to control levels, and insulin release
in response to 25 mmol/L glucose was signiﬁcantly im-
proved compared with treatment with proinﬂammatory
cytokines alone (Fig. 2A). This protective effect can still be
seen to a lesser extent with 1 mmol/L drug but is lost at
50 mmol/L (a dose at which no reduction in 12-HETE was
observed) and when the effect of ML351 is bypassed by the
addition of 100 nmol/L 12-HETE (Fig. 2A). The differences
seen in GSIS assays were not caused by signiﬁcant differ-
ences in total insulin content in islets (Fig. 2B).
To clarify the mechanism underlying the protective
effects of ML351, we performed RNA sequencing analysis
of islets treated with and without cytokines and with and
without 10 mmol/L ML351. Principal component analysis
showed distinct sample group clustering in the absence/
presence of cytokines, with the addition of ML351 having
less-pronounced effects than cytokines (Supplementary Fig.
1). When comparing the effect of ML351 in the presence
of cytokines (by using false discovery rate ,0.05 and fold
change .2.0) (Fig. 2C), we found enrichment for genes
corresponding to pathways responsive to extracellular sig-
nals, metabolism, and oxidative stress (Fig. 2D). Supple-
mentary Table 3 lists all signiﬁcantly altered genes.
Previously, we demonstrated that 12-HETE inhibits the
nuclear translocation of the antioxidant transcription factor
Nrf2 (11). As a readout of antioxidant activity in b-cells, we
examined both an Nrf2 response element reporter in b-cell
lines and ROS production in primary islets in response to
ML351 treatment. As shown in Fig. 2E, when bTC3 cells
transfected with the Nrf2 response element reporter were
treated with 10 mmol/L ML351, no signiﬁcant change in
luciferase reporter activity was observed. When cells were
treated with cytokines alone, a signiﬁcant increase in lucif-
erase activity was seen, which was increased further upon
treatment with increasing doses of ML351 from 1 to
30 mmol/L. In accordance with the Nrf2 responses seen
in the bTC3 cells, Fig. 2F shows that ML351 reversed the
stimulation of ROS production in mouse islets in response
to proinﬂammatory cytokines in vitro. A similar effect was
observed in human islets treated with the human-speciﬁc
12-LOX inhibitor ML355 (Fig. 2G). Together, these results
are consistent with an intracellular reduction in ROS in
response to ML351 treatment.
Table 1—Pharmacokinetic properties of ML351 in C57BL/6J mice
Tissue
Cmax
(ng/mL or ng/g)* tmax (h)
AUC0-∞
(ng/mL $ h or ng/g $ h) t1/2 (h)
IP injection
Plasma 454 1 1,106 9.4
Brain 119 4 1,573 5.2
Fat 5,293 4 67,798 4.6
Liver 131 4 1,837 6.2
Pancreas 255 4 3,199 4.1
PO delivery
Plasma 135 1 698 21.4
Brain 159 4 1,941 3.3
Fat 620 4 7,835 4.3
Liver 157 4 1,911 3.1
Pancreas 57 4 700 3.4
*Data units presented as nanograms per milliliter plasma or nanograms/gram tissue weight.
diabetes.diabetesjournals.org Hernandez-Perez and Associates 2879
ML351 Protects Against STZ-Induced Diabetes in Mice
In pharmacokinetic studies in C57BL/6J mice, we analyzed
the clearance of ML351 from the circulation tissues after IP
and per os (PO) administration at 48 mg/kg (a dose
previously used in mouse models of stroke) (16,17). Higher
plasma and tissue levels (Cmax) of ML351 were achieved
after IP dosing than after PO dosing, and among the tissues
analyzed (brain, fat, liver, pancreas), the drug preferentially
distributed to fat (Table 1). Relatively greater distribution
into pancreas was achieved after IP injection compared with
PO delivery; therefore, we elected to pursue IP dosing for
our models of diabetes in vivo.
We next asked whether ML351 protects against diabetes
development in an STZ b-cell injury model that mimics the
inﬂammation seen in T1D. C57BL/6J mice were adminis-
tered ﬁve daily low doses of STZ, after which they were
followed for the development of diabetes. In addition,
mice were injected daily with a range of ML351 concentra-
tions (0 [M0], 10 [M10], 24 [M24], or 48 [M48] mg/kg)
starting 5 days before the beginning of the STZ series and
concluding 5 days after the last dose of STZ (Fig. 3A). As
shown in Fig. 3B, nanomolar levels of drug were measurable
in plasma just before STZ; these levels directly correlated
with the dosages administered. Animals that received STZ
had signiﬁcant reductions in weight compared with the
no-STZ controls (Fig. 3C). However, at the end of the study,
animals receiving STZ + M10 or STZ + M24 showed signif-
icantly less weight reduction than STZ + M0 animals; un-
expectedly, the body weights of STZ + M48 animals
resembled that of the STZ + M0 controls (Fig. 3C). More-
over, these two treatment groups (STZ + M0 and STZ +
M48) exhibited frank hyperglycemia by day 9 of the study
Figure 3—12/15-LOX inhibition protects against glycemic deterioration after multiple low-dose STZ injections. Nine-week-old male C57BL/6J
mice were treated with vehicle or ML351. Multiple low-dose STZ injections (55 mg/kg) were given for 5 days (n = 5–15). A: Study design.
B: Serum drug levels. C: Change in body weight from the start of the study. D: Random fed blood glucose measurements performed throughout
the study. E: Results of GTTs performed at day 8. F: AUC from GTTs presented in E. G: GSIS in vivo. H: Results of ITTs performed at day 18.
I: Area over the curve (AOC) from ITTs presented in H. Data are mean6 SEM. *P< 0.05 compared with no-STZ + M0. #P< 0.05 compared with
STZ + M0.
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(Fig. 3D) and signiﬁcantly impaired GTTs (Fig. 3E and F). By
contrast, animals administered STZ + M10 and STZ + M24
showed almost complete protection from hyperglycemia
(Fig. 3D), and their GTTs were indistinguishable from ani-
mals not receiving STZ or animals receiving ML351 only
(M10 or M48) (Fig. 3E and F). The improvement in glyce-
mic control in the STZ + M10 animals was accompanied by
improvements in GSIS in vivo (Fig. 3G). Although STZ treat-
ment led to slight worsening of insulin tolerance compared
with animals not receiving STZ, the addition of ML351 did
not affect peripheral glucose utilization response to insulin
in insulin tolerance tests (ITTs) (Fig. 3H and I).
ML351 Preserves b-Cell Mass and Attenuates
STZ-Induced Oxidative Stress
As shown in representative images in Fig. 4A, islets of STZ +
M0 and STZ + M48 animals were signiﬁcantly reduced in
size compared with non-STZ–treated controls, whereas STZ +
M10 animals had islets that were indistinguishable from
controls. Quantitative analysis of b-cell mass (Fig. 4B) dem-
onstrated that the animals receiving STZ + M0 and STZ +
M48 had statistically signiﬁcantly reduced mass compared
with non-STZ–treated controls, whereas animals in the STZ +
M10 and STZ + M24 groups maintained statistically nor-
mal mass. Consistent with the b-cell mass ﬁndings, random
insulin levels were reduced in the STZ + M0 and STZ + M48
groups compared with non-STZ–treated controls but were
preserved in the animals receiving the lower doses of ML351
(Fig. 4C). Together, these data suggest that the lower doses
of ML351 (10 and 24 mg/kg) protect b-cells from STZ.
The deleterious effects of 12-HETE are likely partly due
to its inhibition of Nrf2-mediated transcription of antiox-
idant genes (11,41). We next immunostained pancreas tis-
sues from STZ-treated and control animals for a marker of
oxidative stress and for Nrf2. As shown in Fig. 5A, the
remaining b-cells in mice treated with STZ + M0 exhibited
a signiﬁcant increase in 4-HNE staining, a marker of oxidative
Figure 4—Effect of 12/15-LOX inhibition on b-cell mass and serum insulin in the multiple low-dose STZ diabetes mouse model. Nine-week-old
male C57BL/6J mice were treated with vehicle or ML351. Multiple low-dose STZ injections (55 mg/kg) were given for 5 days (n = 5–15).
A: Representative images of pancreata immunostained for insulin (brown) and counterstained for hematoxylin (blue). Original magniﬁcation3100;
scale bars = 200 mm. B: b-Cell mass of pancreata harvested at day 21. C: Random fed serum insulin levels. Data are mean 6 SEM. *P < 0.05
compared with no-STZ + M0.
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stress (11). In contrast, 4-HNE staining was reduced to
control levels in STZ + M10 and STZ + M24 mice. The
increased 4-HNE staining seen in STZ + M0 mice correlated
with a statistically signiﬁcant decrease in Nrf2 nuclear lo-
calization in b-cells, a ﬁnding that was slightly, but signif-
icantly, reversed in STZ + M10 and STZ + M24 mice (Fig.
5B). Immunostaining for GPX1, a target of Nrf2 activation,
was accordingly decreased in b-cells of STZ + M0 mice but
rescued to control levels in STZ + M24 and STZ + M10 mice
(Fig. 5C).
ML351 Protects Against Early Glycemic Deterioration
in NOD Mice
Female NOD mice develop spontaneous autoimmune di-
abetes between 12 and 24 weeks of age (5,30). A prelude to
the development of diabetes in this model is b-cell dysfunc-
tion and consequent dysglycemia, which are evident as early
as 6 weeks of age (5,42). To assess whether pharmacologic
inhibition of 12/15-LOX protects against the early glycemic
deterioration characteristic of this model, we administered
24 mg/kg of ML351 (M24) or vehicle (M0) by IP injection
daily to female NOD mice beginning at 6 weeks of age for
2 weeks and then assessed glycemic control at 8 weeks of
age; for comparison of the effects of the drug on a non-
diabetes-prone strain, CD1 mice (an outbred strain closely
related to NOD mice) were treated in parallel. Although
fed blood glucose values at 8 weeks of age showed no dif-
ferences between treated and untreated animals of either
strain (Fig. 6A), GTTs showed that NOD + M24 animals
exhibited improved glycemic control compared with NOD +
M0 animals (Fig. 6B and C). CD1 + M0 and CD1 + M24
animals exhibited indistinguishable GTTs, suggesting that
the drug had no effect on this strain (Fig. 6B and C). Anal-
ysis of pancreas from mice (Fig. 6D) revealed that b-cell
mass was unaffected by administration of ML351 in either
strain (Fig. 6E), signifying an effect of the drug on b-cell
function in NOD animals. Consistent with improved b-cell
function, a signiﬁcant reduction in insulitis (Fig. 6D) and
mean insulitis score (Fig. 6F) was observed in NOD + M24
Figure 5—Inhibition of 12/15-LOX protects against islet oxidative stress in the multiple low-dose STZ diabetes mouse model. Nine-week-old
male C57BL/6J mice were treated with vehicle or ML351. Multiple low-dose STZ injections (55 mg/kg) were given for 5 days (n = 5–15). Fixed
pancreatic sections were subjected to immunoﬂuorescence staining. Shown are representative images and the pixel density or nuclear/cyto-
plasmic ratio from analysis of at least three animals per group. A: Oxidative stress marker 4-HNE (magenta), insulin (green), and DAPI (blue).
B: Nrf2 (magenta), insulin (green), and DAPI (blue). C: Antioxidant enzyme GPX1 (magenta), insulin (green), and DAPI (blue). Original magniﬁ-
cation 3200; scale bars = 50 mm. *P < 0.05 compared with no-STZ + M0.
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mice compared with NOD + M0 controls. Because insulitis is
characterized by macrophages in early prediabetic NODmice
(43) and 12/15-LOX is also expressed in macrophages, we
asked whether ML351 treatment affected the prevalence of
anti-inﬂammatory, galectin 3–positive macrophages in the
inﬁltrate (44). As shown in Supplementary Fig. 2, the insu-
litic inﬁltrate of NOD + M24 animals had a signiﬁcantly
greater percentage of galectin 3–positive macrophages than
NOD + M0 animals.
Finally, we examined pancreatic tissue from CD1 and
NOD mice for the presence of oxidative stress. b-Cells from
NOD + M24 mice showed protection against oxidative
stress (4-HNE staining) compared with NOD + M0 controls
(Fig. 7A). This ﬁnding in NOD + M24 animals was consis-
tent with increased b-cell Nrf2 nuclear localization (Fig. 7B)
and increased GPX1 immunoreactivity (Fig. 7C) compared
with NOD + M0 animals. ML351 had no effect on any of
these parameters in CD1 mice (Fig. 7A–C).
DISCUSSION
The LOXs catalyze oxygenation of polyunsaturated fatty acids
to form hydroperoxy fatty acids (e.g., 12-HETE) that generate
ROS (45,46). In mice, 12/15-LOX, encoded by Alox15, con-
tributes negatively to b-cell function (8,11,12,47,48), and
the human 12-LOX enzyme levels are increased in islets of
humans with T1D (49). Notwithstanding its potential role
in T1D pathogenesis, no genetic variants of the LOX en-
zymes in humans have been closely linked to susceptibility
for T1D (50). Nevertheless, given their pervasive roles in
Figure 6—12/15-LOX inhibition mitigates glycemic deterioration in prediabetic NOD mice. Six-week-old NOD and CD1 female mice were
injected daily for 2 weeks with vehicle or 24 mg/kg ML351 (n = 5). A: GTTs performed at 8 weeks of age. B: AUC of GTTs presented in A.
C: Random fed blood glucose at 8 weeks of age. D: Representative images of pancreata immunostained for insulin (brown) and counterstained
with hematoxylin (blue) from prediabetic 8-week-old mice. Original magniﬁcation 3100; scale bars = 100 mm. E: b-Cell mass of pancreata
harvested at week 8. F: Average insulitis score. G: Representative images of pancreata immunostained for glucagon (magenta), insulin (green),
and DAPI (gray). Original magniﬁcation3200; scale bars = 100 mm. *P< 0.05 compared with CD1 + M0. #P< 0.05 compared with NOD + M0.
INS, insulin; NS, not signiﬁcant.
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many diseases, the LOXs have been prime targets for the
development of small-molecule inhibitors. Early attempts to
develop 12/15-LOX inhibitors met with limited success,
with molecules lacking tight speciﬁcity, chemical tractability,
or other drug-like properties. More recently, high-throughput
screening of small-molecule drug libraries followed by
chemical optimization have resulted in a series of com-
pounds with nanomolar potency against 12/15-LOX
(17,23,51). Studies of ML127 have shown promising results
in blocking 12-HETE production in human and mouse islets
(24). Here, we show that ML127 exhibits cytotoxicity at
higher doses. By contrast, ML351 showed negligible cyto-
toxicity in vitro. These ﬁndings might be explained by off-
target interactions, as predicted by computational docking
to the human proteome. On the basis of these ﬁndings, we
pursued ML351 as a prime candidate for 12/15-LOX inhi-
bition in vitro and in vivo.
12-HETE functions as a proinﬂammatory lipid media-
tor (47,48) that increases cellular ROS either directly or
through signaling through the putative receptor Gpr31 (52).
Figure 7—12/15-LOX inhibition reduces islet oxidative stress in prediabetic NOD mice. Fixed pancreatic sections from CD1 and NOD mice
treated with vehicle or 24 mg/kg ML351 were subjected to immunoﬂuorescence staining. Shown are representative images and the pixel density
or nuclear/cytoplasmic ratio from analysis of at least three animals per group. A: Oxidative stress marker 4-HNE (magenta), insulin (green), and
DAPI (blue). B: Nrf2 (magenta), insulin (green), and DAPI (blue). C: Antioxidant enzyme GPX1 (magenta), insulin (green), and DAPI (blue). Original
magniﬁcation 3200; scale bars = 100 mm. *P < 0.05 compared with CD1 + M0.
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Consistent with inhibiting 12/15-LOX, ML351 exposure led
to reduced 12-HETE release from mouse islets, reduced
ROS generation in islets exposed to proinﬂammatory
cytokines, and affected gene pathways involved in hyp-
oxia, cellular death, and the antioxidant response. Although
we did not see direct effects on genes involved in the en-
doplasmic reticulum stress pathway (a response that 12/
15-LOX promotes [11,53]), these gene expression events
likely occur later than the 24-h time point we examined
in vitro (5).
To translate these studies to mouse models of diabetes,
we performed pharmacokinetic studies and found that
ML351 achieves penetrance in key metabolically active
tissues after both IP and PO administration. We initially
used a low-dose STZ mouse model of T1D in which low-
level b-cell death induced by the alkylating effect of STZ
leads to the inﬂux of inﬂammatory cells (e.g., macrophages)
and the subsequent local release of proinﬂammatory cyto-
kines (28,54,55). In this context, the current studies show
that ML351 prevents b-cell oxidative stress, b-cell dysfunc-
tion, and hyperglycemia in treated mice. Of note, a higher
dose of ML351 (48 mg/kg) had no protective effect. Al-
though this ﬁnding indicates an independent toxic effect
of ML351 at higher doses, this seems unlikely because the
mice treated with 48 mg/kg alone showed normoglycemia.
The current studies of ML351 in vitro, wherein higher
doses of the drug (50 mmol/L) failed to inhibit 12-HETE
production or reverse cytokine effects on GSIS, raise the
likely possibility that aggressive inhibition of 12/15-LOX
at high doses of ML351 causes compensatory activity of
another LOX isoform (12-LOX) to generate 12-HETE.
In prior studies, we showed an effect of 12-HETE in
inhibiting the nuclear translocation of Nrf2, thereby prevent-
ing its consequent transcription of genes encoding antioxidant
enzymes (11). We show in the current study that ML351
also enhances activity of an Nrf2 reporter in cell lines and
promotes nuclear translocation of Nrf2 and activation of
GPX1 in b-cells of STZ-treated mice. Given the similarity of
these pharmacologic studies to our earlier pancreas-speciﬁc
knockout studies of Alox15 (11), ML351 possibly inhibited
12/15-LOX directly in b-cells. However, we cannot rule out
that inhibition of 12/15-LOX in macrophages may have also
contributed to the b-cell–protective effect in this model.
Given the relative scarcity of macrophage inﬁltration in
the STZ model (54), quantitative assessment of the effects
of ML351 on macrophages is difﬁcult. In this regard, the
NODmodel provides more insight. Treatment of NOD mice
with ML351 led to improved glycemic control and signiﬁ-
cantly reduced insulitis. The reduction of b-cell death in
NOD mice has been suggested to lead to reductions in insu-
litis, likely by mitigating the chemotactic signals released by
dying b-cells (4,5). On the other hand, we observed that
galectin 3–positive anti-inﬂammatory macrophages make
up a greater percentage of the insulitic inﬁltrate, which
points to a possible direct effect of the drug on macro-
phages. In this regard, ROS has been proposed as an
important mediator of immune cell pathogenicity that
allows for initiation and propagation of insulitis (56).
Treatment with ML351, therefore, may mitigate insulitis
by reducing ROS production in innate and adaptive im-
mune cells.
Although this study is an important ﬁrst step toward
the translation of a new drug class for the prevention of
diabetes, signiﬁcant hurdles remain. Whereas the LOXs
are structurally homologous between mice and humans,
differences in function and spatial expression of LOXs
exist between the species. As noted, the LOX encoded by
Alox15 is the primary LOX expressed in mouse b-cells
and macrophages, whereas in humans this LOX is
encoded by ALOX12. In biochemical studies, ML351 dem-
onstrated.250-fold selectivity for the human LOX encoded
by ALOX15 versus ALOX12 (23). As such, ML351 would not
be an ideal choice for targeting the relevant LOX in hu-
man b-cells and macrophages. Conversely, a related drug,
ML355, exhibits selectivity for human LOX encoded by
ALOX12 (21,25) and appears to have similar effects on re-
ducing human islet ROS production (shown here). Unfor-
tunately, ML355 cannot as yet be tested in preclinical models
in vivo. This limitation to preclinical testing must await either
the selection of a better model organism or the humanization
of the mouse Alox15 alleles. In the meantime, the studies
presented here offer an important new insight into the
feasibility of inhibiting 12/15-LOX for the prevention and
treatment of T1D.
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